ArticleStem cell research & therapy2025
Adjunct cell therapy for hypoplastic left heart syndrome: therapeutic promise requires targeted design strategy.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Letter to the editor regarding: Gallego-Navarro C, Jaggers J, Burkhart HM, Carlo WF, Morales DL, Qureshi MY, Rossano JW, Hagen CE, Seisler DK, Peral SC, Nelson TJ. Autologous umbilical cord blood mononuclear cell therapy for hypoplastic left heart syndrome: a nonrandomized control trial of the efficacy and safety of intramyocardial injections. Stem Cell Res Ther. 2025 May 1;16(1):215. doi: https://doi.org/10.1186/s13287-025-04316-3 . This phase IIb clinical cell therapy trial with autologous cord blood mononuclear cells is notable and highly commended as an important effort in very challenging clinical conditions in which new cell treatment advancements have been limited. In light of their findings of unfavourable clinical findings, our letter highlights that their study is intertwined with the complexity of the clinical pathology within immature pediatric hearts, cardiac surgical intervention strategy and other related study design hurdles. These difficulties contribute to confound the interpretation of cell treatment efficacy and clinical safety. Based on this study and our own recent clinical study, we make a call for future studies testing cell therapy in the congenital heart disease setting, to implement far greater consideration of the mode and timing of cell delivery and congruency with myocardial tissue remodelling and developmental growth processes in small hearts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.